These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35063014)

  • 1. A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.
    Aillaud I; Kaniyappan S; Chandupatla RR; Ramirez LM; Alkhashrom S; Eichler J; Horn AHC; Zweckstetter M; Mandelkow E; Sticht H; Funke SA
    Alzheimers Res Ther; 2022 Jan; 14(1):15. PubMed ID: 35063014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display.
    Malhis M; Kaniyappan S; Aillaud I; Chandupatla RR; Ramirez LM; Zweckstetter M; Horn AHC; Mandelkow E; Sticht H; Funke SA
    Chembiochem; 2021 Nov; 22(21):3049-3059. PubMed ID: 34375027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirror-Image Phage Display for the Selection of D-Amino Acid Peptide Ligands as Potential Therapeutics.
    Malhis M; Funke SA
    Curr Protoc; 2024 Feb; 4(2):e957. PubMed ID: 38372457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purpurin modulates Tau-derived VQIVYK fibrillization and ameliorates Alzheimer's disease-like symptoms in animal model.
    Viswanathan GK; Shwartz D; Losev Y; Arad E; Shemesh C; Pichinuk E; Engel H; Raveh A; Jelinek R; Cooper I; Gosselet F; Gazit E; Segal D
    Cell Mol Life Sci; 2020 Jul; 77(14):2795-2813. PubMed ID: 31562564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease.
    Dammers C; Yolcu D; Kukuk L; Willbold D; Pickhardt M; Mandelkow E; Horn AH; Sticht H; Malhis MN; Will N; Schuster J; Funke SA
    PLoS One; 2016; 11(12):e0167432. PubMed ID: 28006031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of a d-Enantiomeric Peptide Specifically Binding to PHF6 for Inhibiting Tau Aggregation in Transgenic Mice.
    Zhang X; Zhang X; Zhong M; Zhao P; Guo C; Li Y; Wang T; Gao H
    ACS Chem Neurosci; 2020 Dec; 11(24):4240-4253. PubMed ID: 33284003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane-mediated fibrillation and toxicity of the tau hexapeptide PHF6.
    Fanni AM; Vander Zanden CM; Majewska PV; Majewski J; Chi EY
    J Biol Chem; 2019 Oct; 294(42):15304-15317. PubMed ID: 31439664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the Inhibitory Mechanism of Naphthoquinone-Dopamine on the Aggregation of Tau Core Fragments PHF6* and PHF6.
    Zou Y; Qi B; Tan J; Guan L; Zhang Q; Sun Y; Huang F
    ACS Chem Neurosci; 2023 Sep; 14(17):3265-3277. PubMed ID: 37585669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terminal Capping of an Amyloidogenic Tau Fragment Modulates Its Fibrillation Propensity.
    Arya S; Ganguly P; Arsiccio A; Claud SL; Trapp B; Schonfeld GE; Liu X; Lazar Cantrell K; Shea JE; Bowers MT
    J Phys Chem B; 2020 Oct; 124(40):8772-8783. PubMed ID: 32816481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating in vitro and in silico approaches to evaluate the "dual functionality" of palmatine chloride in inhibiting and disassembling Tau-derived VQIVYK peptide fibrils.
    Haj E; Losev Y; Guru KrishnaKumar V; Pichinuk E; Engel H; Raveh A; Gazit E; Segal D
    Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1565-1575. PubMed ID: 29634991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Aggregation Mechanism of Acetylated PHF6* and PHF6 Tau Peptides Based on Molecular Dynamics Simulations and Markov State Modeling.
    Shah SJA; Zhang Q; Guo J; Liu H; Liu H; Villà-Freixa J
    ACS Chem Neurosci; 2023 Nov; 14(21):3959-3971. PubMed ID: 37830541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Amination Converts Amyloidogenic Tau Peptides into Soluble Antagonists of Cellular Seeding.
    Makwana KM; Sarnowski MP; Miao J; Lin YS; Del Valle JR
    ACS Chem Neurosci; 2021 Oct; 12(20):3928-3938. PubMed ID: 34609825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of two VQIXXK motifs for tau fibrillization in vitro.
    Li W; Lee VM
    Biochemistry; 2006 Dec; 45(51):15692-701. PubMed ID: 17176091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tau amyloid formation and disruption of its preformed fibrils by Naphthoquinone-Dopamine hybrid.
    Paul A; Viswanathan GK; Huber A; Arad E; Engel H; Jelinek R; Gazit E; Segal D
    FEBS J; 2021 Jul; 288(14):4267-4290. PubMed ID: 33523571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural transitions in tau k18 on micelle binding suggest a hierarchy in the efficacy of individual microtubule-binding repeats in filament nucleation.
    Barré P; Eliezer D
    Protein Sci; 2013 Aug; 22(8):1037-48. PubMed ID: 23740819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of site-specific amino acid D-isomerization on β-sheet transition and fibril formation profiles of Tau microtubule-binding repeat peptides.
    Tochio N; Murata T; Utsunomiya-Tate N
    Biochem Biophys Res Commun; 2019 Jan; 508(1):184-190. PubMed ID: 30471859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity.
    Frenkel-Pinter M; Tal S; Scherzer-Attali R; Abu-Hussien M; Alyagor I; Eisenbaum T; Gazit E; Segal D
    Neurodegener Dis; 2017; 17(2-3):73-82. PubMed ID: 27760426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease.
    Ryan P; Patel B; Makwana V; Jadhav HR; Kiefel M; Davey A; Reekie TA; Rudrawar S; Kassiou M
    ACS Chem Neurosci; 2018 Jul; 9(7):1530-1551. PubMed ID: 29782794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau-aggregation inhibitors derived from Streptomyces tendae MCCC 1A01534 protect HT22 cells against okadaic acid-induced damage.
    Liu X; She W; Sung HH; Williams ID; Qian P
    Int J Biol Macromol; 2023 Mar; 231():123170. PubMed ID: 36621732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.